Date: 2015-01-12
Type of information: Development agreement
Compound: closed processing system for cell therapy manufacturing
Company: Neostem (USA - NY) Invetech (USA - CA)
Therapeutic area: Technology - Services
Type agreement: development
Action mechanism:
Disease:
Details: * On January 12, 2015,NeoStem, a leader in the development and manufacturing of cell therapy products and regenerative medicine, and Invetech, a global leader in instrument development, custom automation and contract manufacturing,announced an agreement for the development of a new closed processing system (the \"System\") for cell therapy manufacturing. Under the agreement, Invetech will provide system design and engineering development and NeoStem will develop applications for performing closed cell processing manipulations such as separation. The agreement envisions NeoStem as the commercial supplier of the System which would constitute its first branded entry into the cell therapy tools market. The System will be applicable to a range of cell therapy processes in development and commercialization stages, and will consist of an instrumentation platform, disposable flow path, and operating and application software for automated execution of user-selected protocols. The System will provide a flexible small scale process suitable for GMP manufacturing of autologous and other patient-specific products where small scale is full scale, while also supporting efficient development of processes at lower cost prior to transitioning to scaled volumes.
Financial terms:
Latest news:
